Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-24), Basilea Pharmaceutica's 12-1 Month Momentum % is 10.32%.
The industry rank for Basilea Pharmaceutica's 12-1 Month Momentum % or its related term are showing as below:
XSWX:BSLN's 12-1 Month Momentum % is ranked better than 69.79% of 1354
companies
in the Biotechnology industry
Industry Median: -20.965
vs XSWX:BSLN: 10.32
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Basilea Pharmaceutica 12-1 Month Momentum % Related Terms
XSWX:BSLN vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a 12-1 Month Momentum % of 10.32% as of Aug. 24, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #409 out of 1354 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Basilea Pharmaceutica's 12-1 Month Momentum % too high?
Basilea Pharmaceutica's current 12-1 Month Momentum % is 10.32%. Based on the distribution chart, Basilea Pharmaceutica ranks #409 out of 1354 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #409 out of 1354 companies for 12-1 Month Momentum %. This puts Basilea Pharmaceutica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current 12-1 Month Momentum % is 10.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF59.46, compared to a current price of CHF64.60 — trading 8.6% above its estimated fair value. The current 12-1 Month Momentum % is 10.32%. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current 12-1 Month Momentum % is 10.32% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued.
The current stock price of CHF64.60 is trading 8.6% above its estimated GF Value™ of CHF59.46.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
12-1 Month Momentum %: 10.32%
GF Value™: CHF59.46 vs. price of CHF64.60 (8.6% above fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
